Literature DB >> 8313789

Flow cytometric study of lymphocyte subsets in patients at different stages of colorectal carcinoma.

M C Arista1, A Callopoli, L De Franceschi, A Santini, M Schiratti, L Conti, F Di Filippo, G M Gandolfo.   

Abstract

PURPOSE: The evaluation of lymphocyte subsets by using monoclonal antibodies in neoplastic patients has provided different results, partly in relation to the stage of the disease. Therefore, as a preliminary study of cancer patients treated with immunomodulating drugs, an analysis of lymphocyte subsets was performed in colorectal carcinoma patients.
METHODS: In this study, a flow cytometric evaluation of lymphocyte subsets was performed in 33 patients affected by colorectal carcinoma, with or without metastases.
RESULTS: A significant reduction of hemoglobin concentrations and hematocrit was observed in all of these subjects, associated with an evident increase of white blood cells, platelets, and HLA DR-positive T lymphocytes, whereas CD 3-CD 4-positive and CD 20-positive lymphocyte concentrations were decreased. Subjects without metastases showed an evident decrease of hemoglobin concentrations and an increase of white blood cells, platelets and CD 3-HLA DR-positive lymphocytes, while patients with disseminated disease also had reduced mean values of hematocrit, red blood cells, CD 3-CD 4-positive, and CD 20-positive lymphocytes.
CONCLUSIONS: The main differences between colorectal carcinoma patients with or without metastases were represented by a decrease of red blood cells, CD 3-CD 4-positive, and CD 20-positive lymphocyte concentrations in the latter group.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8313789     DOI: 10.1007/bf02048428

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  1 in total

1.  Reduction in cytokine production in colorectal cancer patients: association with stage and reversal by resection.

Authors:  A G Heriot; J B Marriott; S Cookson; D Kumar; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.